GSK – $1B SiranBio Oligo Deal
GSK has signed an oligonucleotide licensing agreement with China-based SiranBio worth up to $1 billion to develop SA030, a Phase 1-stage ALK7-targeting therapy for metabolic disease and abdominal fat reduction.
SiranBio
